Protalix BioTherapeutics, Inc.
PLX
$2.22
-$0.14-5.93%
AMEX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -41.05% | 269.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.05% | 269.98% | |||
| Cost of Revenue | 88.08% | -82.44% | |||
| Gross Profit | -59.04% | 305.92% | |||
| SG&A Expenses | 1.97% | -13.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.79% | -8.53% | |||
| Operating Income | -77.91% | 553.97% | |||
| Income Before Tax | -77.01% | 542.65% | |||
| Income Tax Expenses | -61.65% | 287.91% | |||
| Earnings from Continuing Operations | -79.38% | 432.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -79.38% | 432.79% | |||
| EBIT | -77.91% | 553.97% | |||
| EBITDA | -76.44% | 604.57% | |||
| EPS Basic | -79.42% | 431.50% | |||
| Normalized Basic EPS | -77.04% | 541.33% | |||
| EPS Diluted | -78.55% | 417.92% | |||
| Normalized Diluted EPS | -76.87% | 524.27% | |||
| Average Basic Shares Outstanding | 0.17% | 0.43% | |||
| Average Diluted Shares Outstanding | -0.59% | 4.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||